← Back to Search

Anticoagulant

Weight Based Dosing for Deep Vein Thrombosis (WeBET Trial)

Phase 4
Waitlist Available
Research Sponsored by Intermountain Health Care, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

WeBET Trial Summary

Hospitalized trauma patients frequently suffer from blood clots in the legs or lungs. To minimize the risk of these blood clots developing, patients may be given a blood-thinner drug such as enoxaparin. Until now, a set dose of enoxaparin has been given to a patient, regardless of his or her weight. However, a recent study suggests that for obese patients, the set dose may be inadequate. The purpose of this study is to evaluate whether or not a dose of enoxaparin that is based on the patient's weight will help to prevent the formation of blood clots. The information gathered through this study will help doctors to understand the best way to prevent blood clots in future trauma patients. The potential risks of participating in this study include the minor risks of blood draws and ultrasounds, as well as the more significant risks of bleeding as a side effect of the enoxaparin.

Eligible Conditions
  • Deep Vein Thrombosis

WeBET Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Asymptomatic lower-extremity DVT identified during hospitalization
Secondary outcome measures
Asymptomatic proximal DVT during hospitalization
Major Bleeding
Symptomatic PE during hospitalization and at 90 Days
+3 more

WeBET Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Weight Based DosingExperimental Treatment1 Intervention
Patients will receive weight adjusted VTE prophylaxis of enoxaparin SQ every 12 hours.
Group II: Standard DosingActive Control1 Intervention
Patients will receive standard VTE prophylaxis of enoxaparin SQ every 12 hours.

Find a Location

Who is running the clinical trial?

Intermountain Health Care, Inc.Lead Sponsor
137 Previous Clinical Trials
1,961,910 Total Patients Enrolled
5 Trials studying Deep Vein Thrombosis
2,719 Patients Enrolled for Deep Vein Thrombosis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~101 spots leftby May 2025